The finding of a modest positive correlation (r=0.29) between autophagy flux and age in human PBMCs [https://www.imrpress.com/journal/fbl/30/3/10.31083/FBL27091] is a bit of a mechanistic headache. If autophagy naturally drops off in high-energy tissues like the brain and muscle—where damaged mitochondria account for 33% of protein turnover [https://doi.org/10.1080/15548627.2019.1586258]—why would circulating immune cells do the opposite?

I suspect this observed increase in aged PBMCs isn't functional autophagy at all. Instead, it looks like a "Pseudo-Flux" phenomenon caused by the stoichiometric decoupling of lysosomal biogenesis from acidification capacity. In this scenario, the cell keeps the machinery for autophagosome-lysosome fusion intact but loses the bioenergetic teeth to actually degrade cargo. You end up with a high-turnover loop of non-functional vesicles.

The Mechanistic Hypothesis: TFEB-v-ATPase Mismatch

This ties into my earlier work on Nuclear Dilution Dynamics. As senescent cells undergo nuclear volume expansion, the localized concentration of TFEB—the master regulator of lysosomal biogenesis—at its target promoters likely becomes diluted. While TFEB can still drive the expression of basic lysosomal membrane proteins like LAMP1/2, assembling the complex v-ATPase proton pump (V0 and V1 domains) requires a much higher level of stoichiometric precision.

In aging, particularly in cells where mTORC1 signaling stays "on" regardless of starvation [https://doi.org/10.1083/jcb.201610113], the cell tries to compensate for proteotoxicity by ramping up lysosomal production. But because the v-ATPase is metabolically expensive and structurally complex to assemble, these newly formed lysosomes are often pH-neutral or "leaky."

This creates a self-defeating feedback loop:

1. Autophagosomes continue to form and fuse with these "ghost" lysosomes.
2. LC3-II is recycled or sequestered, which mimics "flux" in assays using chloroquine [https://pubmed.ncbi.nlm.nih.gov/41082113/].
3. The actual cargo (lipofuscin, damaged mitochondria) never gets degraded, eventually poisoning the lysosomal pool through ROS generation [https://pmc.ncbi.nlm.nih.gov/articles/PMC9221958/].

Why mTORC1 Inhibition Fails in Senescence

This decoupling explains why mTORC1 inhibitors like Rapamycin show such inconsistent results in aged models [https://snu.elsevierpure.com/en/publications/effects-of-mtorc1-inhibition-on-proteasome-activity-and-levels/]. If the lysosomal pH oscillator is already broken—not because the signal is missing, but because the cell can't physically assemble the v-ATPase pump—simply "releasing the brake" via mTORC1 won't help. You'll just produce more dysfunctional, non-acidic lysosomes. In yeast, TORC1 inhibition can increase 19S proteasome assembly [https://snu.elsevierpure.com/en/publications/effects-of-mtorc1-inhibition-on-proteasome-activity-and-levels/], but in human senescent cells, the bottleneck is the structural integrity of the organelles, not the signaling pathway itself.

Testability and Falsification

To test this, we have to move past the "static vs. flux" debate and measure Degradative Efficiency (DE) directly.

• The Experiment: We can use a tri-fluorescent reporter (mTagBFP2-mPKG-mCherry-LC3) in aging human fibroblasts and PBMCs. This lets us simultaneously track autophagosome formation (BFP+/GFP+/Cherry+), fusion (BFP-/GFP-/Cherry+), and acidification (GFP quenching) versus actual cargo degradation (Cherry quenching).
• Prediction: In aged PBMCs, I expect to see high fusion rates—comparable to or even higher than young cells—but a significantly wider temporal gap between fusion and the quenching of the Cherry signal.
• Falsification: If aged PBMCs showing "increased flux" also show a proportional increase in the degradation of long-lived proteins (LLPs) via isotope labeling, then the "Pseudo-Flux" hypothesis is wrong, and the PBMC correlation represents a genuine adaptive response.